Does nano‐curcumin supplementation improve hematological indices in critically ill patients with sepsis? A randomized controlled clinical trial. Issue 5 (12th February 2022)

• Record Type: Journal Article
• Authors: Naeini, Fatemeh; Tutunchi, Helda; Razmi, Hamidreza; Mahmoodpoor, Ata; Vajdi, Mahdi; Sefidmooye Azar, Pouria; Najifipour, Farzad; Tarighat‐Esfanjani, Ali; Karimi, Arash
• Is Part Of: Journal of food biochemistry. Volume 46:Issue 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-12
• Subjects: Hematological indices -- immune responses -- Nano‐curcumin -- sepsis; Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; Biochemistry -- Periodicals; 664.024
• DOI: 10.1111/jfbc.14093
• Languages: English
• ISSNs: 0145-8884

Abstract

Abstract: Sepsis is the final common pathway to death for severe infectious diseases worldwide. The present trial aimed to investigate the effects of nano‐curcumin supplementation on hematological indices in critically ill patients with sepsis. Fourteen ICU‐admitted patients were randomly allocated into either nano‐curcumin or placebo group for 10 days. The blood indices, serum levels of inflammatory biomarker and presepsin as well as nutrition status, and clinical outcomes were assessed before the intervention and on days 5 and 10. White blood cells, neutrophils, platelets, erythrocyte sedimentation rate (ESR), and the levels of interleukin‐8 significantly decreased in the nano‐curcumin group compared to the placebo after 10 days of intervention ( p = .024, p = .045, p = .017, p = .041, and p = .004, respectively). There was also a marginal meaningful decrease in serum presepsin levels in the intervention group compared to the placebo at the end of the study ( p = .054). However, total lymphocyte count showed a significant increase in the nano‐curcumin group compared to the placebo at the end‐point ( p = .04). No significant differences were found in the level of lymphocyte and the ratios of neutrophil/lymphocyte and platelet/lymphocyte between the study groups. Moreover, no significant between‐group differences were observed for other study outcomes, post‐intervention. Collectively, nano‐curcumin may be a useful adjuvant therapy in critically ill patients with sepsis. However, further trials are suggested to examine the effects of nano‐curcumin in the management of sepsis and its complications. Practical applications: Curcumin (1, 7‐bis[4‐hydroxy‐3‐methoxyphenyl]‐1, 6‐heptadiene‐3, 5‐ dione) or diferuloylmethane is widely used in medicine due to its several biological properties. Recent evidence has shown that curcumin possesses multiple pharmacological activities including immune‐modulatory, antioxidant, anti‐inflammatory, anti‐cancer, and anti‐microbial effects. In this study, it was observed that nano‐curcumin at a dose of 160 mg for 10 days, without side effects, reduced some inflammatory factors and regulated the immune responses in sepsis patients. For the first time, this trial was conducted to determine the effect of nano‐curcumin on hematological indices and the serum levels of presepsin and IL‐8. Abstract : Sepsis pathogenesis.